Circadian variation of topoisomerase II-α in human rectal crypt epithelium: Implications for reduction of toxicity of chemotherapy

Modern Pathology

Volumn 15, Issue 11, 2002, Pages 1191-1196

  Clayton, Frederic ^a,c   Tessnow, Kathryn A ^b   Fang, John C ^b   Holden, Joseph A ^c   Moore, John G ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse effects; Circadian rhythm; Colon; DNA topoisomerase II; Doxorubicin; Drug therapy; Etoposide; Rectum

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); PEROXIDASE; PROTEIN SUBUNIT; THYMIDINE;

ADULT; ARTICLE; CELL NUCLEUS; CHEMOTHERAPY; CIRCADIAN RHYTHM; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN TISSUE; MOLECULAR BIOLOGY; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM BIOPSY; STAINING; TOXICITY;

ADOLESCENT; ADULT; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CHRONOTHERAPY; CIRCADIAN RHYTHM; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; EPITHELIUM; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; RECTUM;

EID: 0036861142     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000032529.68297.B2     Document Type: Article

References (45)

1. Fisher LB. The diurnal mitotic rhythm in the human epidermis. Br J Dermatol 1968;80:75-80.
2. Scheving LE. Mitotic activity in the human epidermis. Anat Rec 1959;135:7-20.
3. Zugula-Mally ZW, Cardoso SS, Williams D, Simpson H, Reinberg A. Time point differences in skin mitotic activity of actinic keratoses and skin cancer. In: Reinberg A, Halberg F, editors. Chronopharmacology. New York: Pergamon; 1979. p. 399-402.
4. Bjarnason GA, Jordan RC, Sothern RB. Circadian variation in the expression of cell-cycle proteins in human oral epithelium. Am J Pathol 1999;154(2):613-22.
5. Buchi KN, Moore JG, Hrushesky WI, Sothern RB, Rubin NH. Circadian rhythm of cellular proliferation in the human rectal mucosa. Gastroenterology 1991;101(2):410-5.
6. Marra G, Anti M, Percesepe A, Armelao F, Ficarelli R, Coco C, et al. Circadian variations of epithelial cell proliferation in human rectal crypts. Gastroenterology 1994;106(4):982-7.
7. Smaaland R, Laerum OD, Lote K, Sletvold O, Sothern RB, Bjerknes R. DNA synthesis in human bone marrow is circadian stage dependent. Blood 1991;77(12):2603-11.
8. Smaaland R, Sothern RB. Circadian cytokinetics of murine and human bone marrow and human cancer. In: Hrushesky WIM, editor. Circadian Cancer Therapy. Boca Raton, FL: CRC Press; 1994. p. 119-63.
9. Mormont MC, Boughattas N, Levi F. Mechanisms of circadian rhythms in the toxicity and efficacy of anticancer drugs: Relevance for the development of new analogs. In: Lemmer B, editor. Chronopharmacology. New York: Marcel Dekker; 1989. p. 395-437.
10. Bjarneson GA, Hrushesky WIM. Cancer chemotherapy. In: Hrushesky WIM, editor. Circadian Cancer Therapy. Boca Raton, FL: CRC Press; 1994. p. 241-63.
11. Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997;350(9079):681-6.
12. Levi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial. J Natl Cancer Inst 1994;86(21):1608-17.
13. Levi F, Zidani R, Brienza S, Dogliotti L, Perpoint B, Rotarski M, et al. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. Cancer 1999;85(12):2532-40.
14. Wang JC. DNA topoisomerases. Annu Rev Biochem 1996;65: 635-92.
15. Adachi Y, Luke M, Laemmli UK. Chromosome assembly in vitro: Topoisomerase II is required for condensation. Cell 1991;64(1):137-48.
16. DiNardo S, Voelkel K, Sternglanz R. DNA topoisomerase II mutant of Saccharomyces cerevisiae: Topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proc Natl Acad Sci U S A 1984; 81(9):2616-20.
17. Holm C, Stearns T, Botstein D. DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage. Mol Cell Biol 1989;9(1):159-68.
18. Heck MM, Hittelman WN, Earnshaw WC. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 1988;85:1086-90.
19. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH- 3T3 cells. Cell Growth Differ 1991; 2(4):209-14.
20. Holden JA. Human deoxyribonucleic acid topoisomerases: Molecular targets of anticancer drugs. Ann Clin Lab Sci 1997;27(6):402-12.
21. Corbett AH, Osheroff N. When good enzymes go bad: Conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem Res Toxicol 1993;6(5):585-97.
22. Nitiss JL, Wang JC. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharmacol 1996;50(5):1095-102.
23. Ohdo S, Makinosumi T, Ishizaki T, Yukawa E, Higuchi S, Nakano S, et al. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice. J Pharmacol Exp Ther 1997; 283(3):1383-8.
24. Holden JA, Townsend JJ. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: Correlation with MIB1 expression and patient survival. Mod Pathol 1999;12(12):1094-100.
25. Mojon A, Fernandez JR, Hermida RC. Chronolab: An interactive software package for chronobiologic time series analysis written for the Macintosh computer. Chronobiol Int 1992;9:302-12.
26. Sothern RB, Voegelen M, Mattson O, Hrushesky WJM. A chronobiological Statistical Package for Personal Computer. Chronobiologica 1989;16:184.
27. Bauman ME, Holden JA, Brown KA, Harker WG, Perkins SL. Differential immunohistochemical staining for DNA topoisomerase II alpha and beta in human tissues and for DNA topoisomerase II beta in non-Hodgkin's lymphomas. Mod Pathol 1997;10(3):168-75.
28. Maurer HR. Potential pitfalls of [3H] thymidine techniques to measure cell proliferation. Cell Tissue Kinet 1981;14(2):111-20.
29. Bjarnason GA, Jordan RC, Wood PA, Li Q, Lincoln DW, Sothern RB, et al. Circadian expression of clock genes in human oral mucosa and skin: Association with specific cell-cycle phases. Am J Pathol 2001;158(5):1793-801.
30. Scheving LE, Burns ER, Pauly JE, Tsai TH. Circadian variation in cell division of the mouse alimentary tract, bone marrow and corneal epithelium. Anat Rec 1978;191(4):479-86.
31. Hrushesky WJ. Circadian timing of cancer chemotherapy. Science 1985;228(4695):73-5.
32. Kobayashi M, Wood PA, Hrushesky WJ. Circadian chemotherapy for gynecological and genitourinary cancers. Chronobiol Int 2002;19(1):237-51.
33. Barrett RJ, Blessing JA, Homesley HD, Twiggs L, Webster KD. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 1993;16(6):494-6.
34. Canal P, Sqall A, de Forni M, Chevreau C, Pujol A, Bugat R, et al. Chronopharmacokinetics of doxorubicin in patients with breast cancer. Eur J Clin Pharmacol 1991;40(3):287-91.
35. Eksborg S, Stendahl U, Antila K. Pharmacokinetics of 4′ epi-adriamycin after morning and afternoon intravenous administration. Med Oncol Tumor Pharmacother 1989;6(3):195-7.
36. Minami H, Ratain MJ, Ando Y, Shimokata K. Pharmacodynamic modeling of prolonged administration of etoposide. Cancer Chemother Pharmacol 1996;39(1-2):61-6.
37. Kuhl JFW, Grage TB, Halberg F, Rosene G, Scheving L, Haus E. Ellen-effect. Tolerance of adriamycin by Bagg albino mice and Fisher rats depends on circadian timing of injection. Int J Chronobiol 1973;1(1):335.
38. Peleg L, Ashkenazi IE, Carlebach R, Chaitchik S. Time-dependent toxicity of drugs used in cancer chemotherapy: Separate and combined administration. Int J Cancer 1989;44(2):273-5.
39. Levi F, Halberg F, Haus E, Sanchez de la Pena S, Sothern RB, Halberg E, et al. Synthetic adrenocorticotropin for optimizing murine circadian chronotolerance for adriamycin. Chronobiologia 1980;7(2):227-44.
40. Granda TG, Filipski E, D'Attino RM, Vrignaud P, Anjo A, Bissery MC, et al. Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination. Cancer Res 2001;61(5):1996-2001.
41. Davies GJ, Macdonald J, Halberg F, Simpson HW. Circadian rhythm in murine tolerance of daunorubicin [letter]. Lancet 1974;2(7883):779.
42. Levi F, Mechkouri M, Roulon A, Bailleul F, Lemaigre G, Reinberg A, et al. Circadian rhythm in tolerance of mice for the new anthracycline analog 4′-O-tetrahydropyranyl-adriamycin (THP). Eur J Cancer Clin Oncol 1985;21(10):1245-51.
43. Levi F, Blazsek I, Ferle-Vidovic A. Circadian and seasonal rhythms in murine bone marrow colony-forming cells affect tolerance for the anticancer agent 4′-O-tetrahydropyranyladriamycin (THP). Exp Hematol 1988;16(8):696-701.
44. Mormont MC, von Roemeling R, Sothern RB, Berestka JS, Langevin TR, Wick M, et al. Circadian rhythm and seasonal dependence in the toxicological response of mice to epirubicin. Invest New Drugs 1988;6(4):273-83.
45. Levi F, Mechkouri M, Roulon A, Bailleul F, Horvath C, Reinberg A, et al. Circadian rhythm in tolerance of mice for etoposide. Cancer Treat Rep 1985;69(12):1443-5.